The tariff classification of Carbidopa/Levodopa Tablets and Methocarbamol Tablets from India

N006949 March 9, 2007 CLA-2-30:RR:E:NC:2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9140 Mr. Colm Moynihan NorthStar Healthcare Limited 3300 Cork Airport Business Park Cork, Ireland RE: The tariff classification of Carbidopa/Levodopa Tablets and Methocarbamol Tablets from India Dear Mr. Moynihan: In your letter dated February 13, 2007, you requested a tariff classification ruling. The first product, Carbidopa/Levodopa Tablets, is a medicinal preparation, in tablet form, containing Carbidopa (CAS-28860-95-9 (anhydrous)) and Levodopa (CAS-59-92-7) as active ingredients. Carbidopa/Levodopa Tablets are indicated for the treatment of Parkinson’s disease. The second product, Methocarbamol Tablets, is a medicinal preparation, in tablet form, containing Methocarbamol (CAS-532-03-6), a skeletal muscle relaxant, as the active ingredient. Methocarbamol Tablets are used in the treatment of muscle spasm. The applicable subheading for both products will be 3004.90.9140, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the central nervous system: Other.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. These products may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. In your letter, you also requested a ruling on Enalapril Maleate Tablets and Benazepril Hydrochloride Tablets. We note that this office, in NY Ruling Letter N006197, issued to you on February 22, 2007, ruled on the tariff classification of Enalapril Maleate Tablets. We also note that this office, in NY Ruling Letter N006196, also issued to you on February 22, 2007, ruled on the tariff classification of Benazepril Tablets. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 CFR 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division